Pfizer has declared its numbers for the quarter ended August 2009 (Q3). Its net profit went up 8.3% at Rs 41.15 crore as against Rs 38 crore in the same period of last year.

Kewal Handa said Pfizer grew at a higher rate than the industry.

The industry has grown at about 12.4% whereas Pfizer has grown at about 13.8%. So, we are growing really higher than the industry and both higher than the multinational and Indian companies as far as the IMS data.

We have done 15% growth on a year-to-date (YTD) basis and profits are growing at about 3%. On a quarterly basis, the growth has been 9% with the profit growing at about 8%.

On a YTD basis, we are about Rs 500 crore, and on the basis of quarter, we did about Rs 200 crore this quarter.

EBITDA margins are at around about 24% against the previous quarter of 21%.

I think that has already been released by Pfizer where some vaccines are getting divested. That has no impact as far as India’s operation is concerned.